Neuropathological and cell type‐specific effects of Kv1.3 blockers in a pre‐clinical AD mouse model
Upasna Srivastava, Christine A Bowen, Prateek Kumar, Maureen Sampson, Hailian Xiao, Hollis Zeng, Anson Sing, Caitlin Sojka, Tarun Bhatia, Heike Wulff, Steven A Sloan, Srikant Rangaraju, Department of Neurology · 2025
Read Neuropathological and cell type‐specific effects of Kv1.3 blockers in a pre‐clinical AD mouse model by Upasna Srivastava, Christine A Bowen, Prateek Kumar, Maureen Sampson, Hailian Xiao, Hollis Zeng, Anson Sing, Caitlin Sojka, Tarun Bhatia, Heike Wulff, Steven A Sloan, Srikant Rangaraju, Department of Neurology (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11709989.txt.
Description
Upasna Srivastava and co-authors present a 2025 conference abstract on blocking a potassium channel to calm brain inflammation. The channel, Kv1.3, sits on immune cells and is a drug target in Alzheimer's disease. Two blockers were tested in 5xFAD mice: a small molecule in chow and a peptide given by injection, from six to nine months of age.
Both blockers lowered amyloid plaque burden. Only the small molecule, PAP-1, also lowered a key amyloid measure and improved fear learning. Single-cell gene readouts from about 137,000 cortical cells showed the drug hit microglia hardest. The work separates shared effects from drug-specific ones.
Catalog record
| CREATOR | Upasna Srivastava, Christine A Bowen, Prateek Kumar, Maureen Sampson, Hailian Xiao, Hollis Zeng, Anson Sing, Caitlin Sojka, Tarun Bhatia, Heike Wulff, Steven A Sloan, Srikant Rangaraju, Department of Neurology |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |